Remove tag national-institute-health-and-care-research
article thumbnail

Grand Rounds October 20, 2023: A National Initiative to Eliminate Hepatitis C in the United States – Why This Matters to Clinical Trialists (Rachael L. Fleurence, PhD, MSc; Joshua M. Sharfstein, MD)

Rethinking Clinical Trials

Fleurence, PhD, MSc Senior Advisor National Institutes of Health Joshua M. There is a lack of point-of-care diagnostics; it can take up to 3 steps to treatment initiation. The treatment is not a routine part of primary care, and there is an underserved and hard-to-reach population.       Speakers Rachael L.

article thumbnail

New Rare Disease Drugs and Research Advancements

XTalks

Rare Disease Day 2024, which falls on February 29 this year, is an opportunity to unite under a common cause: to bring attention to the challenges faced by those living with rare diseases and to push for advancements in research, treatment and policy. In 2020, 31 out of 53 novel drug approvals were for rare or orphan diseases​​.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access

pharmaphorum

Access to medicines remains one of the most challenging policy areas in every country we work with through the pan-European region,” said Natasha Muscat, Director of Country Health Policies and Systems at World Health Organization (WHO) Europe. Flawed funding model.

article thumbnail

Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA

XTalks

With a price tag of over $2.5 In England, five-month old baby Arthur became the country’s first SMA patient to receive the Zolgensma gene therapy last week through the National Health Service (NHS). Every year, approximately 40 children are born with the most severe form of SMA. Baby Arthur: First UK Patient.

article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. This alone causes expense for cash-strapped hospitals and puts pressure on nursing and medical staff while they manage the side effects.

article thumbnail

How data is crucial to the relaunch of the Cancer Moonshot

pharmaphorum

During the first stage of the initiative, more than 2,000 research papers were published, 49 clinical trials were carried out, and more than 30 patents were filed through the support of the US National Cancer Institute (NCI). Building a bank.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The Health Survey for England 2019 reported that 28% of adults in the UK were obese and 36.2% A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% In 1997, the World Health Organization (WHO) classified obesity as a chronic disease. The UK and US are both undergoing an obesity crisis.

Drugs 264